JP2013510885A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510885A5
JP2013510885A5 JP2012539065A JP2012539065A JP2013510885A5 JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5 JP 2012539065 A JP2012539065 A JP 2012539065A JP 2012539065 A JP2012539065 A JP 2012539065A JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5
Authority
JP
Japan
Prior art keywords
formula
composition
compound
nhch
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510885A (ja
JP5650233B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056760 external-priority patent/WO2011060392A1/en
Publication of JP2013510885A publication Critical patent/JP2013510885A/ja
Publication of JP2013510885A5 publication Critical patent/JP2013510885A5/ja
Application granted granted Critical
Publication of JP5650233B2 publication Critical patent/JP5650233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539065A 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 Active JP5650233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US61/261,301 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013235966A Division JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Division JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Publications (3)

Publication Number Publication Date
JP2013510885A JP2013510885A (ja) 2013-03-28
JP2013510885A5 true JP2013510885A5 (enExample) 2014-01-09
JP5650233B2 JP5650233B2 (ja) 2015-01-07

Family

ID=43992106

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539065A Active JP5650233B2 (ja) 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP3868377A1 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101721716B1 (enExample)
CN (2) CN105061350B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR112012011427B8 (enExample)
CA (2) CA2780772C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK3406142T3 (enExample)
EA (2) EA035768B1 (enExample)
ES (2) ES2858337T3 (enExample)
FI (1) FI2498610T4 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE037535T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT3406142T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY189750A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL3406142T3 (enExample)
PT (2) PT2498610T (enExample)
RS (2) RS61829B1 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI3406142T1 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012011430A8 (pt) * 2009-11-13 2017-12-26 Celgene Int Ii Sarl Compostos moduladores de receptor de esfingosina 1 fosfato e composições farmacêuticas
HUE037535T2 (hu) 2009-11-13 2018-09-28 Celgene Int Ii Sarl Szelektív szfingozin-1-foszfát receptor modulátorok és királis szintézis eljárások
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
BR112014031565B1 (pt) * 2012-06-21 2022-04-12 Eisai R&D Management Co., Ltd Derivado de indanossulfamida inovador
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
WO2016164180A1 (en) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
CN109219597A (zh) 2016-06-14 2019-01-15 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
WO2018014862A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 S1p1激动剂及其应用
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
CN108137516A (zh) * 2016-09-14 2018-06-08 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
EP3508481A1 (en) * 2016-09-14 2019-07-10 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of ozanimod hydrochloride, and preparation method therefor
KR102408814B1 (ko) 2016-09-29 2022-06-14 리셉토스 엘엘씨 루푸스를 치료하기 위한 화합물 및 방법
JP7123956B2 (ja) * 2017-02-28 2022-08-23 ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド スピロ化合物およびその使用
WO2018184185A1 (zh) * 2017-04-07 2018-10-11 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
US11207301B2 (en) 2017-05-08 2021-12-28 Receptos Llc Sphingosine 1 phosphate receptor agonists for neuroprotection
HRP20231308T1 (hr) * 2017-05-22 2024-04-26 Egis Gyógyszergyár Zrt. Postupak za proizvodnju ozanimoda
US10278960B2 (en) 2017-06-23 2019-05-07 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
EP3677575A4 (en) * 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
BR112020014488A2 (pt) * 2018-01-18 2020-12-01 Shijiazhuang Sagacity New Drug Development Company, Ltd. formas cristalinas e salinas do composto tricíclico e processo de preparação das mesmas
MX2020009100A (es) 2018-03-20 2020-12-03 Eisai R&D Man Co Ltd Agente de tratamiento de la epilepsia.
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
EP3810285B1 (en) 2018-06-25 2025-02-12 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CA3109673A1 (en) 2018-09-12 2020-03-19 Pharmazell Gmbh A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020115200A1 (en) 2018-12-07 2020-06-11 Synthon B.V. Improved process for preparing ozanimod
WO2020205481A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
US20220144788A1 (en) * 2019-03-29 2022-05-12 Receptos Llc Sphingosine 1 phosphate receptor modulators
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
JP2022529845A (ja) * 2019-04-26 2022-06-24 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
EP3999495A1 (en) 2019-07-16 2022-05-25 Synthon B.V. Improved process for preparing ozanimod
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
KR20220124209A (ko) * 2020-01-06 2022-09-13 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 이상의 치료 방법
US11760751B2 (en) 2020-03-04 2023-09-19 Helioeast Science & Technology Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
WO2021175225A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 三环类化合物及其应用
US11554111B2 (en) 2020-03-17 2023-01-17 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
WO2021195397A1 (en) * 2020-03-27 2021-09-30 Receptos Llc Sphingosine 1 phosphate receptor modulators
JP7653447B2 (ja) * 2020-03-27 2025-03-28 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１ホスフェート受容体モジュレーター
WO2021197852A1 (en) 2020-04-02 2021-10-07 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
EP4321507A4 (en) * 2021-04-09 2025-04-09 Helioeast Pharmaceutical Co., Ltd. Oxadiazole-substituted spirocyclic compound and use thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
JPH0825973B2 (ja) 1991-04-12 1996-03-13 シェリング・コーポレーション アシル補酵素ａ：コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
TR200002072T2 (tr) * 1998-01-23 2000-12-21 Sankyo Company Limited Spiropiperidin türevleri
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2509218C (en) * 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en) 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
BRPI0614090A2 (pt) † 2005-08-03 2011-03-09 Novartis Ag uso de inibidores da hdac para o tratamento do mieloma
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
JP5514443B2 (ja) 2005-12-21 2014-06-04 ジョセフ ガブリエル， カテコールアミン調節性タンパク質
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
ES2393412T3 (es) * 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
MX2009006304A (es) * 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008143729A2 (en) 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
EP2913326B1 (en) * 2008-05-14 2020-07-15 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
BR112012011430A8 (pt) * 2009-11-13 2017-12-26 Celgene Int Ii Sarl Compostos moduladores de receptor de esfingosina 1 fosfato e composições farmacêuticas
CN105130922A (zh) 2009-11-13 2015-12-09 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
HUE037535T2 (hu) 2009-11-13 2018-09-28 Celgene Int Ii Sarl Szelektív szfingozin-1-foszfát receptor modulátorok és királis szintézis eljárások
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Similar Documents

Publication Publication Date Title
JP2013510885A5 (enExample)
JP2015505296A5 (enExample)
JP2014506907A5 (enExample)
JP2016534063A5 (enExample)
JP2011527691A5 (enExample)
JP2013032389A5 (enExample)
JP2013537203A5 (enExample)
JP2012092103A5 (enExample)
SI2498610T1 (en) SELECTIVE MODERATORS OF SFINGOSIN-1-PHOSPHATE RECEPTOR AND CIRAL SYNTHESIS PROCEDURES
JP2009242409A5 (enExample)
JP2012532883A5 (enExample)
JP2009535358A5 (enExample)
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
JP2020507589A5 (enExample)
JP2009504748A5 (enExample)
JP2009542613A5 (enExample)
JP2010536766A5 (enExample)
JP2018537535A5 (enExample)
JP2013542992A5 (enExample)
JP2015535847A5 (enExample)
JP2010529994A5 (enExample)
JP2009543795A5 (enExample)
JP2013533253A5 (enExample)
JP2013514980A5 (enExample)
JP2019516739A5 (enExample)